Compare Sanofi SA (SNY) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Clear Secure Inc — how do they compare? Sanofi SA trades at $43.48 (market cap $104.30B), while Clear Secure Inc trades at $46.88 (market cap $4.98B). The key difference: Sanofi SA is far larger — about 20.9× Clear Secure Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | YOU | |
|---|---|---|
Market Cap | $104.30B | $4.98B |
Sector | Health | Technology |
52-Week High | $52.34 | $62.36 |
52-Week Low | $41.33 | $29.61 |
Enterprise Value | $124.19B | $4.13B |
Dividend Yield | 5.55% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Clear Secure (YOU) trades at $47.31, down 7.63% over 24 hours, reflecting a bearish technical trend with support near $45. Fundamentally, the company reported strong Q2 2026 earnings of $0.49 per share, beating estimates, with revenue growth to $1.0 billion projected for 2026 and a net income margin of 14.78%. Recent news highlights expansion of its CLEAR1 platform and corporate membership launches, driving investor optimism despite recent price pressure.
The outlook is mixed: robust earnings beats and strategic initiatives support growth, but high valuation ratios (P/E of 32.62) and bearish technical signals pose risks. Analysts are divided with a 44% buy rating, suggesting cautious optimism amid volatility. Key risks include execution challenges and competitive pressures in identity verification services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
